Company
About Sartar
We are Sartar Therapeutics, a small and experienced team dedicated to the development of novel targeted therapies for hard-to-treat cancers. We discovered a novel cancer target phosphodiesterase 3A (PDE3A), with exceptionally high expression in gastrointestinal stromal tumor (GIST), other soft tissue sarcoma subtypes and subsets of other cancers.
Our Vision
Our Mission
To bring hope and relief to patients suffering from hard-to-treat cancers. We believe that every patient deserves a chance to fight cancer with the best science and technology available. We are driven by passion, curiosity and compassion. We value collaboration, innovation and excellence in everything we do.
Our operative team
CHIEF EXECUTIVE OFFICER
Mikael Maksimow
Chief Executive Officer Mikael Maksimow has Master’s Degree in Biotechnology and Ph.D. in Immunology. Mikael has a long experience in early drug development from discovery stages to clinical trials, as well as experience in startup business development.
CHIEF DEVELOPMENT OFFICER
Maria Lahtinen
Chief Development Officer Maria Lahtinen is Ph.D. in chemistry and has Bachelor’s Degree in Industrial Engineering and Management. Maria has almost 20 years of experience in various drug development activities from laboratory to phase III clinical trials.
HEAD OF CLINICAL DEVELOPMENT
Charlotta Backman
Head of Clinical Development, Charlotta Backman has more than 20 years of experience in clinical development. Over the course of her career, Charlotta has been involved in Phase I–IV clinical trials across a wide range of therapeutic indications. Last 15 years with a focus on early-stage development within oncology.
PROJECT MANAGER
Satu Koskimies
Project Manager Satu Koskimies is a life sciences professional with an M.Sc. in molecular biology. Satu has extensive experience across medicinal product and medical device development, encompassing clinical research, quality assurance, regulatory affairs, CMC, medical writing, and contract management.
CHIEF MEDICAL OFFICER
Jussi Koivunen
Chief Medical Officer Jussi Koivunen is M.D. Ph.D with a board certification on clinical oncology. Jussi has long exprience on cancer reasearch from bench to bedside. Furthemore, he has hold previous positions in pharmaceutical industry.
Board of Directors
FOUNDER, CHAIRMAN OF THE BOARD
Harri Sihto, Ph.D.
The Chairman of the Board, Dr. Harri Sihto is a founding member of the Company. He is a biochemist, who received his Ph.D. degree in 2012 and was awarded with title of Adjunct Professor of Cancer Biology in 2015 at the University of Helsinki. Dr. Sihto’s research group investigates novel therapy targets in sarcomas and other rare cancers to discover new therapeutic options for the patients.
FOUNDER, BOARD MEMBER
Olli Kallioniemi, M.D., Ph.D.
Professor Olli Kallioniemi is a founder and board member of Sartar Therapeutics. Professor Kallioniemi is an expert in precision medicine. As a founding director of the Institute of Molecular Medicine Finland (FIMM), he had a crucial role in building a national research infrastructure required for precision medicine research. Now Prof. Kallioniemi is the Director of Science for Life Laboratory, Stockholm, Sweden.
BOARD MEMBER
Jami Mandelin, Ph.D.
Jami Mandelin has a strong background in the pharmaceutical industry and in academic research. Currently he is the CEO of Kasvu Therapeutics Ltd. Mandelin has a vast experience from early drug discovery to pivotal clinical studies. He has also been developing biomarker programs and launching companion diagnostics.
BOARD MEMBER
Martti Kiuru, M.D., Ph.D., M.Sc., Specialist in radiology
Adjunct professor Martti Kiuru has long and strong experience in healthcare business in various positions; as an entrepreneur, CEO and board member. Kiuru has also served and is serving on boards of several other industries.